57 results about "Vascular leakage" patented technology

The invention relates to the technical field of medical image information processing, discloses an ICG fluorescence image and MRCP three-dimensional model registration fusion display method and system, effectively solves the problems of deep biliary tract structure blurring and form distortion caused by liver tissue scattering effect in intraoperative fluorescence imaging, uses a preoperative model as anatomical prior, and improves the accuracy of the intraoperative fluorescence imaging. A viewpoint correlation optical path depth field is constructed through reverse ray tracing, a spatial variation point spread function is generated accordingly, physical reverse recovery of scattering halo in a fluorescence image is achieved, non-specific background noise such as vascular leakage is effectively inhibited in combination with topological gravitational constraint of a central skeleton, and the detection accuracy is improved. The real pipe diameter and the center line position of the deep bile duct are accurately recovered, non-rigid registration correction is performed on the three-dimensional model based on the recovered high-fidelity image, and projection errors caused by respiratory movement and soft tissue deformation are eliminated.

The invention provides a monoclonal antibody 6G2 resisting DENV NS1 protein and application of the monoclonal antibody 6G2. The CDR amino acid sequence of a heavy chain of the monoclonal antibody 6G2 resisting the DENV NS1 protein is shown as SEQ ID No.1, and the CDR amino acid sequence of a light chain of the monoclonal antibody 6G2 resisting the DENV NS1 protein is shown as SEQ ID No.3. The invention also provides application of the monoclonal antibody 6G2 to preparation of drugs for treating dengue virus infection, and the monoclonal antibody 6G2 for resisting DENV NS1 protein has the performances of competitively binding DENV1-4NS1 protein, inhibiting vascular leakage symptoms and protecting DENV infected fatal injury in vivo, and has potential important value for treating severe dengue fever. The monoclonal antibody 6G2 developed by the invention has important significance and application potential for prevention and treatment of dengue virus infection, including severe dengue fever.

Systems and methods relate to processing optical tomography coherence (OCT) images to predict characteristics of a treatment to be administered to effectively treat age-related macular degeneration. The processing can include pre-processing the image by flattening and / or cropping the image and processing the pre-processed image using a neural network. The neural network can include a deep convolutional neural network. An output of the neural network can indicate a predicted frequency and / or interval at which a treatment (e.g., anti-vascular endothelial growth factor therapy) is to be administered so as to prevent leakage of vasculature in the eye.

The invention provides a traceable mitochondrial targeting nano system as well as a preparation method and application thereof, and belongs to the field of medicines. The traceable mitochondrial targeting nano system constructed by the invention can continuously release resveratrol and maintain the photochemical stability of resveratrol. The nano system shows efficient cellular uptake and accurate mitochondrial targeting ability, and promotes removal of mitochondrial ROS and adjustment of mitochondrial autophagy, so that vascular leakage and angiogenesis are relieved, in-vivo microvascular hyperplasia and retina degeneration are remarkably inhibited, and the curative effect is improved. The distribution of the compound in fundus can be monitored in real time through clinical ophthalmological diagnosis equipment, and the compound has a good application prospect in preparation of drugs for preventing and / or treating diabetic retinopathy.

The present application provides a method for detecting pseudo-lesions of the fundus, comprising: performing image feature analysis of the lesion area according to preliminary lesion markings, locating and evaluating the cell density and the degree of vascular leakage, and determining the risk of disease aggravation; predicting the tortuosity and vascular fragility of new blood vessels and evaluating the probability of complications in patients according to morphological processing and feature analysis of multi-phase vascular images; predicting the risk of serious complications according to the lesion markings and vascular feature analysis of the patient, combined with blood test results, and re-identifying and excluding pseudo-lesion images that are mistaken for lesion images; comparing the feature changes of pseudo-lesions and real lesion areas according to time series analysis of fundus disease images, evaluating the disease development path, and performing early intervention on the disease; segmenting the new blood vessel area based on the use of sensitive index filtering technology, and evaluating the risk of disease aggravation through vascular feature statistics.

The invention belongs to the field of blood vessel puncture, and discloses a blood vessel leakage hemostasis device convenient for adjusting local pressure, which comprises an equipment terminal, one side of the equipment terminal is connected with a cuff structure, and a plurality of pressure air bags are uniformly arranged in the cuff structure; a plurality of adjusting devices communicated with the pressure air bag in a matched mode are fixedly arranged on the outer side of the cuff structure, and a pulse oximeter is movably arranged at one end of the cuff structure. The invention solves the problems that in the prior art, gauze is usually used for pressurizing, binding and stopping bleeding, but the method has many defects that the pressure is difficult to uniformly distribute, the blood circulation is not smooth due to excessive pressurization, and the bleeding cannot be effectively stopped due to insufficient pressurization. In addition, frequent adjustment is needed in the gauze binding process, manual operation is tedious, and the stable pressurizing effect is difficult to keep continuously, and the device is suitable for damage and leakage of the blood vessel puncture part.

The invention relates to the technical field of drug delivery, and discloses a multilayer drug-loaded microsphere for intraocular sustained-release therapy and a preparation process thereof.The multilayer drug-loaded microsphere comprises a core layer, a middle layer and a shell layer, the core layer is composed of a polylactic acid-glycolic acid copolymer (PLGA) and a first hydrophobic drug, the middle layer is formed by wrapping the core layer with carboxymethyl chitosan, and the shell layer is composed of a first hydrophobic drug and a second hydrophobic drug. The first hydrophobic drug comprises a first therapeutic drug, the middle layer comprises a second therapeutic drug, the shell layer is composed of a polylactic acid-caprolactone copolymer PLCL and a third hydrophilic drug, and the first hydrophobic drug, the second therapeutic drug and the third hydrophilic drug are different from one another. Through the layered design of the core layer, the middle layer and the shell layer and in combination with differential degradation rates of PLGA, carboxymethyl chitosan and PLCL materials, gradient release of hydrophobic and hydrophilic drugs is achieved, a drug release curve is matched with the pathological stage of intraocular diseases, macular degeneration rapidly inhibits vascular leakage in the early stage and continuously resists inflammation in the later stage, and the effect of treating macular degeneration is achieved. And the layered slow-release synergistic treatment effect is verified.

This invention provides a monoclonal antibody 6G2 against DENV NS1 protein and its application. The CDR amino acid sequence of the heavy chain of the monoclonal antibody 6G2 against DENV NS1 protein is shown in SEQ ID No. 1, and the CDR amino acid sequence of the light chain is shown in SEQ ID No. 3. This invention also provides the application of the above antibody in the preparation of drugs for treating dengue virus infection. The monoclonal antibody 6G2 against DENV NS1 protein of this invention has the ability to competitively bind to DENV1-4NS1 protein, inhibit vascular leakage symptoms, and protect against lethal damage from DENV infection in vivo, thus possessing significant potential value in the treatment of severe dengue fever. The monoclonal antibody 6G2 developed by this invention has important significance and application potential for the prevention and treatment of dengue virus infection, including severe dengue fever.

Benzyl derivative compounds having peroxisome proliferator-activated receptor alpha (PPARα) agonist activity, kits and compositions containing such compounds, and methods of using them to enhance PPARα activity to treat diseases and / or conditions involving inflammation and / or angiogenesis, particularly diseases and / or conditions of the eye such as, but not limited to, retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

The present invention relates to a combination preparation comprising: an interleukin-2 (IL-2) immune anticancer drug; and a compound represented by chemical formula 1, a stereoisomer thereof, a crystalline form thereof, or a pharmaceutically acceptable salt thereof, whereby the combination preparation can exhibit the effects of enhancing the efficacy of an interleukin-2 immune anticancer drug and alleviating vascular leakage syndrome, which is a side effect of the interleukin-2 immune anticancer drug. [Chemical formula 1]

Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, kits and compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and / or conditions involving inflammation and / or angiogenesis, particularly ocular diseases and / or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

The invention provides a monoclonal antibody 6D11 and application thereof. The CDR amino acid sequence of a heavy chain of the monoclonal antibody 6D11 is shown as SEQ ID No.1, and the CDR amino acid sequence of a light chain of the monoclonal antibody 6D11 is shown as SEQ ID No.2. The invention also provides application of the monoclonal antibody 6D11 in preparation of drugs for treating dengue virus infection, and the monoclonal antibody 6D11 has the advantages of competitive binding of DENV1-4NS1 protein, inhibition of vascular leakage symptom, in vivo protection of DENV infection fatal injury and the like, and has potential huge treatment value of dengue virus resistance.

This invention provides a monoclonal antibody 6D11 and its applications. The CDR amino acid sequence of the heavy chain of the anti-monoclonal antibody 6D11 is shown in SEQ ID No. 1, and the CDR amino acid sequence of the light chain is shown in SEQ ID No. 2. This invention also provides the application of monoclonal antibody 6D11 in the preparation of drugs for treating dengue virus infection. The monoclonal antibody 6D11 of this invention has advantages such as competitive binding to DENV1-4NS1 protein, inhibition of vascular leakage symptoms, and protection against lethal damage from DENV infection in vivo, and has significant potential therapeutic value against dengue virus.

The present invention discloses engineered platelets carrying platelet activation inhibitor nanoparticles, a preparation method and application thereof, which belongs to the field of pharmaceutical technology and relates to a preparation method of engineered platelets carrying ticagrelor nanoparticles and its therapeutic use in malignant solid tumors. The preparation of the engineered platelets described in the present invention includes the steps of extracting and purifying platelets, preparing gelatin nanoparticles loaded with platelet activation inhibitors, anchoring the nanoparticles to the outer surface of platelets, etc. The engineered platelets of the present invention are targeted to reach the tumor site by recruiting tumor-associated platelets in the body, and specifically respond to matrix metalloproteinases to release the carried platelet activation inhibitor, thereby inhibiting the activation of platelets in the tumor microenvironment, enhancing tumor vascular leakage, alleviating the immunosuppressive microenvironment, and effectively enhancing the effects of chemotherapy and immunotherapy.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

Disclosed herein are 3D printed vascular tissues and compositions and methods for making the 3D printed vascular tissues. The 3D printed vascular tissues can be used to model vascular tissue damage (e.g., vascular leakage) and in screening assays for agents that cause or inhibit or treat vascular tissue damage.

The present invention relates to a pharmaceutical composition for preventing or treating eye diseases, the composition comprising altiratinib or a pharmaceutically acceptable salt thereof as an active ingredient. More specifically, the present invention has been found to inhibit the Wnt / β-catenin signaling pathway and have the effect of suppressing intraocular vascular leakage, and thus can be used as a therapeutic agent for eye diseases such as macular degeneration, retinal edema, and retinal degeneration.

The invention belongs to the technical field of medicines, and particularly relates to application of a pigment epithelium-derived factor (PEDF) in synergistically enhancing a hepatocyte growth factor (HGF) in resisting pulmonary arterial hypertension (PH). Research finds that the HGF can improve pulmonary artery remodeling in PH, but can aggravate vascular leakage through a VEGF / VEGFR2 pathway. The PEDF can be combined with VEGFR2 (vascular endothelial growth factor receptor 2) to inhibit VEGF-induced endothelial cell activation and permeability increase. Meanwhile, a specific region of the PEDF is combined with the VEGFR2 under the action of a hydrogen bond and the like, and a derivative peptide fragment of the PEDF can block a VEGF / VEGFR2 signal. Compared with single HGF, cotransfection of the PEDF and the HGF can better inhibit angiogenesis and leakage and delay PH progress. Researches prove that the PEDF counteracts the leakage promoting side effect of the HGF through specific binding with the VEGFR2, and a theoretical basis is provided for developing a PH treatment strategy of the HGF combined with the PEDF derived peptide.

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.

The present disclosure refers to a fusion protein having an antibody or antigen-binding fragment thereof against Tie-2 and a vascular endothelial growth factor (VEGF) binding domain, a method for making the fusion protein, and pharmaceutical compositions and methods for preventing or treating angiogenic diseases or modulating angiogenesis, endothelial signaling, inflammation and / or vascular leakage comprising the fusion protein.

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

The invention relates to the technical field of biological medicine, in particular to a culture medium for vascular endothelial progenitor cells, a culture method and application, the culture medium for the vascular endothelial progenitor cells is improved, and the prepared vascular endothelial progenitor cells have higher proliferative activity and better angiogenesis ability and have the strongest ability of promoting secretion of active factors. Factors such as IL-10 and TGF-beta secreted by the EPCs have potential functions of inhibiting mast cell degranulation and reducing release of histamine and inflammatory mediators so as to relieve wind mass and pruritus. In addition, the EPCs promote endothelial cell proliferation by secreting VEGF, Ang-1 and other factors, repair damaged vascular endothelium and reduce vascular leakage and edema. In urticaria vasculitis, the EPCs can inhibit hyperplasia of vascular endothelium and relieve chronic inflammation. The culture medium disclosed by the invention can be used for culturing the vascular endothelial progenitor cells, is beneficial to screening potential medicines for treating urticaria, and has a huge application value.

Microparticulate (MP) formulations formed from one or more poly(hydroxyacid) polymers having a molecular weight ranging from 5kD to 60kD, and one or more active agents are injected into the eye of a subject to address eye disorders. The MP formulations assure high drug loading and extended delivery of the active agent of six to twelve months. The active agents may include peroxisome proliferator-activated receptor alpha (PPARα) signaling agonists such as PPARα agonist A190 (IUPAC name 3-((4-((4-fluorobenzyl)oxy)- 3- methylbenzyl)amino)benzoic acid). The formulations have therapeutic and protective effects against retinal degeneration diseases such as age-related macular degeneration (AMD), but may also be used for treating or relieving the symptoms of retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular edema (DME).

The present invention relates to a composition for alleviating, inhibiting, treating or preventing macular degeneration. The composition according to the present invention has excellent effects of reducing angiogenesis due to macular degeneration and inhibiting vascular leakage, and thus can be used as a therapeutic agent for alleviating or treating macular degeneration, particularly age-related macular degeneration (AMD).

The invention discloses application of dihydropyridine in preparation of a medicine for treating choroidal neovascularization, and belongs to the technical field of biological medicines.The proliferation, migration and lumen formation of human choroidal endothelial cells under the hypoxia condition are inhibited through dihydropyridine, and blood vessel leakage, area and volume of laser-induced choroidal neovascularization of mice are reduced; the formation of laser-induced choroidal neovascularization of mice is relieved through dihydropyridine, and the proliferation, migration and lumen formation of hypoxia-induced human choroidal endothelial cells can be down-regulated, so that the PHD has a treatment effect on CNV.

The present disclosure relates to a composition for preventing, alleviating or treating an eye disease, which contains (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester as an active ingredient. The (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester of the present disclosure exhibits the effect of remarkably reducing intraocular vascular leakage and, as such, can be advantageously used in a composition for preventing, alleviating or treating an eye disease.

The application belongs to the field of biological medicine, and discloses an artificially synthesized Sema4D / PlexinB1 inhibitor and application thereof in preparation of a medicine for treating and preventing fundus vascular diseases. The applicant screens Sema4D inhibitors capable of combining with sSema4D and blocking sSema4D-PlexinB1 by using an OBOC library, and finally obtains a protein small peptide KWIIVGA which has high affinity to sSema4D and has a good inhibiting effect on fundus vascular leakage and fundus vascularization of mice in a mouse experiment. The small peptide can effectively inhibit fundus vascularization and leakage, and provides a new idea for the treatment of fundus vascularization and leakage diseases such as diabetic retinopathy.

The present application relates to a crystalline form of (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy-6-(acetoxymethyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopentadienyl[a]phenanthrene-17-yl)hept-5-enoate, and a vascular leakage blocker comprising the crystalline form. The new crystalline form has high purity, excellent stability, excellent long-term storage and drug stability, and can be used as a vascular leakage blocker, so it is very advantageous in producing high-quality drugs.

Benzyl derivative compounds having peroxisome proliferator-activated receptor alpha (PPAR alpha) agonistic activity, kits and compositions comprising such compounds, and methods of their use to enhance PPAR alpha activity for the treatment of diseases and / or disorders involving inflammation and / or angiogenesis, in particular ocular diseases and / or disorders, such as inflammatory diseases and / or angiogenesis. Such as, but not limited to, retinal inflammation, retinal neovascularization, retinal vascular leakage, preterm retinopathy, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

The present invention relates to a method for preparing a novel vascular leakage inhibitor with high yield. The preparation method is easy to react and more productive and economical than the conventional method, using an intermediate agent that can easily remove impurities generated during the reaction. In addition, the preparation method can produce a novel vascular leakage inhibitor with high yield, using a new reagent that has not been used in the isomerization step in the past, and is particularly advantageous in the production of a high-quality active pharmaceutical ingredient.